Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience
Aim:Despite dramatic progress in the treatment of pediatric solid tumors in the last 3 decades, confronting a relapsed or refractory patient is still challenging. We report our experience of refractory/relapsed pediatric solid tumor patients treated with vincristin + topotecan + cyclophosphamide (VT...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayinevi
2019-09-01
|
| Series: | Journal of Pediatric Research |
| Subjects: | |
| Online Access: |
http://jpedres.org/archives/archive-detail/article-preview/results-of-vincristine-cyclophosphamide-and-topote/30527
|
| _version_ | 1797914866100469760 |
|---|---|
| author | Uğur Demirsoy Funda Çorapçıoğlu Meriban Karadoğan |
| author_facet | Uğur Demirsoy Funda Çorapçıoğlu Meriban Karadoğan |
| author_sort | Uğur Demirsoy |
| collection | DOAJ |
| description | Aim:Despite dramatic progress in the treatment of pediatric solid tumors in the last 3 decades, confronting a relapsed or refractory patient is still challenging. We report our experience of refractory/relapsed pediatric solid tumor patients treated with vincristin + topotecan + cyclophosphamide (VTC) as a salvage therapy.Materials and Methods:Eleven refractory/relapsed patients (5 neuroblastoma, 4 Ewing’s sarcoma, 1 rhabdomyosarcoma and 1 osteosarcoma) who were given VTC as a salvage therapy were evaluated. All of them were metastatic at diagnosis and received appropriate initial chemotherapy. VTC consisted of vincristin (1.5 mg/m2 on day 1), cyclophosphamide (600 mg/m2/day with mesna, on days 1 and 2) and topotecan (1 mg/m2/day on days 1, 2 and 3).Results:Eleven patients received a total of 53 courses of VTC with a median of 4 (range: 2-14). Median age at diagnosis was 12 years. One patient achieved complete response, 6 patients had stable disease, and 4 patients had progressive disease after 2 courses of VTC. The median survival duration was 28 months after diagnosis while it was 16 months after relapse. The median survival duration after first VTC was 5 months (2-21 months). Myelosuppression was the primary dose limiting toxicity.Conclusion:We concluded that VTC has a clinically tolerable but non-satisfactory effect on relapsed/refractory solid tumors in children. |
| first_indexed | 2024-04-10T12:32:48Z |
| format | Article |
| id | doaj.art-29979be515614304a71f978b79d104c0 |
| institution | Directory Open Access Journal |
| issn | 2147-9445 2587-2478 |
| language | English |
| last_indexed | 2024-04-10T12:32:48Z |
| publishDate | 2019-09-01 |
| publisher | Galenos Yayinevi |
| record_format | Article |
| series | Journal of Pediatric Research |
| spelling | doaj.art-29979be515614304a71f978b79d104c02023-02-15T16:14:48ZengGalenos YayineviJournal of Pediatric Research2147-94452587-24782019-09-016319720210.4274/jpr.galenos.2018.8077413049054Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center ExperienceUğur Demirsoy0Funda Çorapçıoğlu1Meriban Karadoğan2 Kocaeli University Faculty of Medicine, Department of Pediatric Oncology, Kocaeli, Turkey Kocaeli University Faculty of Medicine, Department of Pediatric Oncology, Kocaeli, Turkey Kocaeli University Faculty of Medicine, Department of Pediatric Oncology, Kocaeli, Turkey Aim:Despite dramatic progress in the treatment of pediatric solid tumors in the last 3 decades, confronting a relapsed or refractory patient is still challenging. We report our experience of refractory/relapsed pediatric solid tumor patients treated with vincristin + topotecan + cyclophosphamide (VTC) as a salvage therapy.Materials and Methods:Eleven refractory/relapsed patients (5 neuroblastoma, 4 Ewing’s sarcoma, 1 rhabdomyosarcoma and 1 osteosarcoma) who were given VTC as a salvage therapy were evaluated. All of them were metastatic at diagnosis and received appropriate initial chemotherapy. VTC consisted of vincristin (1.5 mg/m2 on day 1), cyclophosphamide (600 mg/m2/day with mesna, on days 1 and 2) and topotecan (1 mg/m2/day on days 1, 2 and 3).Results:Eleven patients received a total of 53 courses of VTC with a median of 4 (range: 2-14). Median age at diagnosis was 12 years. One patient achieved complete response, 6 patients had stable disease, and 4 patients had progressive disease after 2 courses of VTC. The median survival duration was 28 months after diagnosis while it was 16 months after relapse. The median survival duration after first VTC was 5 months (2-21 months). Myelosuppression was the primary dose limiting toxicity.Conclusion:We concluded that VTC has a clinically tolerable but non-satisfactory effect on relapsed/refractory solid tumors in children. http://jpedres.org/archives/archive-detail/article-preview/results-of-vincristine-cyclophosphamide-and-topote/30527 Refractory solid tumorssalvage chemotherapyVTC treatment |
| spellingShingle | Uğur Demirsoy Funda Çorapçıoğlu Meriban Karadoğan Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience Journal of Pediatric Research Refractory solid tumors salvage chemotherapy VTC treatment |
| title | Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience |
| title_full | Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience |
| title_fullStr | Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience |
| title_full_unstemmed | Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience |
| title_short | Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience |
| title_sort | results of vincristine cyclophosphamide and topotecan protocol in refractory relapsed pediatric solid tumors a single center experience |
| topic | Refractory solid tumors salvage chemotherapy VTC treatment |
| url |
http://jpedres.org/archives/archive-detail/article-preview/results-of-vincristine-cyclophosphamide-and-topote/30527
|
| work_keys_str_mv | AT ugurdemirsoy resultsofvincristinecyclophosphamideandtopotecanprotocolinrefractoryrelapsedpediatricsolidtumorsasinglecenterexperience AT fundacorapcıoglu resultsofvincristinecyclophosphamideandtopotecanprotocolinrefractoryrelapsedpediatricsolidtumorsasinglecenterexperience AT meribankaradogan resultsofvincristinecyclophosphamideandtopotecanprotocolinrefractoryrelapsedpediatricsolidtumorsasinglecenterexperience |